Male and female participants who are healthy Body mass index (BMI) of 17.5 to 30.5 kg/m2;
and a total body weight >50 kg
- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological,
dermatological, or allergic disease
- Any condition possibly affecting drug absorption
- Known immunodeficiency.
- Infection with hepatitis B or hepatitis C viruses
- acute or chronic infections or infection history judged to be clinically significant
by the investigator
- History of any lymphoproliferative disorder
- known present or a history of malignancy other than a successfully treated or excised
non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in
situ.
- live (attenuated) vaccines within 6 weeks prior to the first dose of investigational
product.